葡萄糖类-1受体激动剂和胰腺炎:一个可调和的离婚
Adi E Mehta1, Laura D Lomeli2, Kevin M Pantalone3
1Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic, Cleveland, OH; Clinical Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH mehtaae@ccf.org.
Cleveland Clinic journal of medicine
|August 1, 2025
概括
葡萄糖类-1 (GLP-1) 受体激活剂可能不会增加急性胰腺炎的风险. 最近的研究表明,拒绝这些糖尿病药物给有胰腺炎病史的患者是不合理的.
科学领域:
- 内分泌学 在内分泌学.
- 胃肠病学 胃肠病学
- 临床药理学 临床药理学
背景情况:
- 早期的临床试验表明GLP-1受体激动剂与急性胰腺炎之间存在潜在联系.
- 这导致临床谨慎,避免这些药物在有胰腺炎病史的患者.
研究的目的:
- 重新评估GLP-1受体激动剂与急性胰腺炎风险之间的关联.
- 为了告知临床实践关于这些药物的使用在以前有胰腺炎的患者.
主要方法:
- 对大型临床试验数据的系统审查和元分析.
- 对聚合数据的分析,以评估在接受GLP-1受体激动剂治疗的患者中急性胰腺炎的发生率.
主要成果:
- 最近的大型元分析不支持全类急性胰腺炎风险增加.
- 数据表明,最初的担忧可能被夸大了.
结论:
- 目前的证据不证明在有急性胰腺炎病史的患者中避免GLP-1受体激动剂.
- 这些有价值的治疗药物可以安全地被考虑为符合条件的患者.
相关概念视频
Glucagon-like Receptor Agonists
419
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
419
Dipeptidyl Peptidase 4 Inhibitors
260
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
260
Oral Hypoglycemic Agents: Glinides
263
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
263
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.4K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.4K
Acute Pancreatitis II: Clinical Manifestations and Management
177
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
177
Hypoglycemia and Glucagon
337
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
337


